Ichimori K, Ottesen EA

Language: English
References: 13
Page: 146-149
PDF size: 224.95 Kb.

ABSTRACT

One of the oldest of the neglected tropical diseases, lymphatic filariasis, is caused by filarial worms transmitted by insect vectors that live in the lymphatic system and most commonly cause lymphedema, elephantiasis and hydrocele, which may lead to severe deformity, stigma and disability. Similar to other neglected tropical diseases, lymphatic filariasis occurs mostly among the poor disenfranchised populations living in highly endemic settings perpetuating a cycle that traps people into further poverty and destitution. Through the leadership of the World Health Organization, the Global Programme to Eliminate Lymphatic Filariasis has reached substantial achievements in decreasing the transmission of lympahtic filariasis in multiple settings. The strategic plan for the next 10 years of the Global Programme, in addition to working within the new ‘neglected tropical diseases environment,’ lays out necessary mass drug administration implementation goals for the filariasis-endemic countries that have not yet started their elimination programs (principally in Africa). The neglected tropical diseases programs—and the lymphatic filariasis program in particular—are among the very least expensive, most cost-effective tools to benefit needy populations of the developing world.

REFERENCES

1. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis. Progress report 2000-2009 and strategic plan 2010-2020: halfway towards eliminating lymphatic filariasis. Geneva: World Health Organization; 2010. Contract No.: WHO/HTM/NTD/PCT/2010.6.

2. Ottesen EA. Lymphatic filariasis: treatment, control and elimination. Adv Parasitol 2006;61:395-441.

3. Witt C, Ottesen EA. Lymphatic filariasis: an infection of childhood. Trop Med Int Health 2001;6:582-606.

4. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008;2:e317.

5. Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). PLoS Negl Trop Dis 2010;4:e708.

6. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005;6:179-200.

7. Weil GJ, Lammie PJ, Weiss N. The ICT filariasis test: a rapidformat antigen test for diagnosis of bancroftian filariasis. Parasitol Today 1997;13:401-404.

8. Gustavsen KM, Bradley MH, Wright AL. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. Ann Trop Med Parasitol 2009;103(suppl1):S11-S15.

9. Eisai Public Relations Department. Eisai to provide medicine to help World Health Organization (WHO) combat lymphatic filariasis epidemic; 2010. Available at: http://www.eisai.co.jp/enews/enews201066.html.

10. Fenwick A, Molyneux D, Nantulya V. Achieving the millennium development goals. Lancet 2005;365:1029-1030.

11. Dreyer G, Addiss D, Dreyer P, Noroes J. Basic lymphedema management: treatment and prevention of problems associated with lymphatic filariasis. Hollis, NH: Hollis Publishing Company; 2002.

12. Brantus P. Ten years of managing the clinical manifestations and disabilities of lymphatic filariasis. Ann Trop Med Parasitol 2009;103(suppl 1):S5-S10.

13. World Health Organization. Monitoring and epidemiological assessment of mass drug administration in the programme to eliminate lymphatic filariasis. Geneva: World Health Organization. 2011, in press. Contract No.: WHO/HTM/NTD/2011.xx.